IP Library Granted Patent US 7,435,720
Granted Patent B2
US 7,435,720 · App. 11/550,051 · Granted Oct 14, 2008

Compositions and methods for enhanced mucosal delivery of parathyroid hormone

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,435,720
App. No.
11/550,051
Granted
Oct 14, 2008
Kind
B2
Abstract

Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH 1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.

Claims (8)

1. A pharmaceutical aerosol device comprising:

a. an aqueous solution comprising PTH, cyclodextrin and didecanoylphophatidylcholine at concentrations sufficient to enhance permeation across a cellular layer;

b. a container into which the solution is placed; and

c. an actuator fluidly connected to the container adapted to produce an aerosol spray out of a tip of the actuator when actuated, wherein the aerosol spray consists of droplets, of which less than 10 % are less than 10 microns in diameter.

2. The device of claim 1 , wherein the aerosol has a spray pattern ellipticity ratio of 1 to 4 when measured at a height of 0.5 cm to 10 cm distance from the actuator tip.

3. The device of claim 1 , wherein the aerosol spray contains 20 to 200 microliters of the solution per actuation.

4. The device of claim 1 , wherein the aerosol spray pattern has major and minor axes of 10 to 50 mm when measured at a height of 0.5 cm to 10 cm distance from the actuator tip.

5. The device of claim 1 , wherein upon actuation an aerosol of the solution is produced through the tip of the actuator, wherein the aerosol is comprised of droplets of the solution that are 25 to 700 microns in size.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2014
From: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 032685/0158 →
SECURITY AGREEMENT Recorded Feb 15, 2012
From: MARINA BIOTECH, INC; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
Reel/Frame 027712/0200 →
RELEASE OF SECURITY INTEREST Recorded Jul 30, 2010
From: CEQUENT PHARMACEUTICALS, INC.
To: MARINA BIOTECH, INC. (F/K/A MDRNA, INC.)
Reel/Frame 024767/0466 →
SECURITY AGREEMENT (PATENTS) Recorded Apr 28, 2010
From: MDRNA, INC. FKA NASTECH PHARMACEUTICAL COMPANY INC.
To: CEQUENT PHARMACEUTICALS, INC.
Reel/Frame 024300/0825 →
CHANGE OF NAME Recorded Sep 5, 2008
From: NASTECH PHARMACEUTICAL COMPANY INC.
To: MDRNA, INC.
Reel/Frame 021487/0575 →